148408-66-6 Docetaxel trihydrate
TDS
148408-66-6
Pharmaceutical Grade
0.98%
shanghai
Ranhang
According to customers demand
2024-05-28
chemical
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceWhite Crystalline PowderChEBI: The trihydrate form of docetaxel. It is used for the treatment of breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer.
Docetaxel trihydrate is the trihydrate form of docetaxel. It is used for the treatment of breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer. It has a role as an antineoplastic agent. It is a hydrate and a secondary alpha-hydroxy ketone. It contains a member of docetaxel anhydrous.|Docetaxel is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumors including breast and lung cancer. Docetaxel therapy is frequently associated with serum enzyme elevations which are usually transient and mild, but more importantly has been linked to rapid onset, severe hypersensitivity reactions that can be associated with acute hepatic necrosis, liver failure and death.|Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)|A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.Certificates-
TDS
Basic Info-
Product Name:
Docetaxel trihydrate
Other Name:Benzenepropanoic acid,β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-,(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,hydrate (1:3),(αR,βS)-;Benzenepropanoic acid,β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-,12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester trihydrate,[2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]-;Benzenepropanoic acid,β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-,(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,trihydrate,(αR,βS)-;7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.;Docetaxel trihydrate;Taxespira;175519-33-2
CAS No.:148408-66-6
Molecular Formula:C43H53NO14.3H2O
InChIKeys:InChIKey=XCDIRYDKECHIPE-QHEQPUDQSA-N
Molecular Weight:861.929
Exact Mass:861.378296
EC Number:1308068-626-2
UNII:15H5577CQD
DSSTox ID:DTXSID80872444
NCI Thesaurus Code:C1526
ATC Code:L01CD02
HScode:2932996560
Categories:
Characteristics-
PSA:
227
Density:1.37 g/cm3
Melting Point:186-192°C
Boiling Point:1016.9°C at 760 mmHg
Flash Point:568.8ºC
Water Solubility:Practically insoluble in water, freely soluble in anhydrous ethanol, soluble in methylene chloride.
Hazard IdentificationClassification of the substance or mixture
Eye irritation, Category 2
Germ cell mutagenicity, Category 2
Reproductive toxicity, Category 1B
Reproductive toxicity, Additional category for effects on or via lactation
Specific target organ toxicity â repeated exposure, Category 1
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H319 Causes serious eye irritation
H341 Suspected of causing genetic defects
H360 May damage fertility or the unborn child
H362 May cause harm to breast-fed children
H372 Causes damage to organs through prolonged or repeated exposure
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P203 Obtain, read and follow all safety instructions before use.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P263 Avoid contact during pregnancy and while nursing.
P270 Do not eat, drink or smoke when using this product.
Response P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P318 IF exposed or concerned, get medical advice.
P319 Get medical help if you feel unwell.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
chemical
-
Location:
Room 237, Office Building, Shangma Yirui Industrial Park, 500 meters east of the intersection of Hedong Road and Longfei Road, Shangma Street, Chengyang District, Qingdao City, Shandong Province
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
2
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
5-10
-
Year of Establishment:
2023
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
\\\
